Hodgkin lymphoma

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Retrieved on: 
星期二, 四月 16, 2024
Compass, FDA, HNSCC, Hodgkin lymphoma, Doctor of Philosophy, PD-1, IND, PD-L1, Therapy, Patient, Melanoma, Head, NSCLC, TNBC, Lung cancer, Pharmaceutical industry

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker.

Key Points: 
  • The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker.
  • CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1.
  • Compass advanced CTX-8371 to the clinic following pre-clinical observations of superior activity when compared with approved checkpoint blockers.
  • BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors.

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
星期一, 四月 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

KEYTRUDA for Ovarian cancer in 7MM: Market Assessment, Competitive Landscape, Forecasts, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 26, 2024
Biotechnology, Health, Oncology, FDA, Safety, SWOT, Carcinoma, EU4, Research, PD-1, Hodgkin lymphoma, Melanoma, Clinical trial, Peripheral tolerance, Cancer, Ovarian cancer, Lung cancer, Pharmaceutical industry

The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
  • Other emerging products for ovarian cancer are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to KEYTRUDA for ovarian cancer?

Affimed Reports 2023 Financial Results and Operational Progress

Retrieved on: 
星期四, 三月 28, 2024
Research, EGFR, GVHD, NSCLC, Genentech, ASH, AML, PD, Disease, International, International Financial Reporting Standards, Patient, Webcast, EFS, EDT, CRS, Cancer, Record, Insurance, Trial of the century, Bank statement, Investment, Safety, Workforce, Roivant Sciences, PFS, IASB, Hodgkin lymphoma, Book, NK, HL, Cytokine release syndrome

MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.

Key Points: 
  • MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
  • Based on the promising results, Affimed expanded enrollment in this cohort to 40 patients.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on March 28, 2024, at 8:30 a.m. EDT / 13:30 CET to discuss full year 2023 financial results and corporate developments.

Summary of opinion: Keytruda, 22/02/2024 Positive

Retrieved on: 
星期日, 三月 10, 2024
Carboplatin, GEJ, Hodgkin lymphoma, Patient, HNSCC, Cervical cancer, Ageing, CHL, Colorectal cancer, ALK, BTC, Head, Large intestine, Neck, Committee, Recurrence, IIC, Marketing, RCC, Renal cell carcinoma, Cancer, TPS, CHMP, Trastuzumab, TNBC, Paclitaxel, ASCT, Axitinib, Transitional epithelium, NSCLC, Lung cancer, European Commission, EGFR, Cholangiocarcinoma, Medication package insert, CRC, Neoplasm, Radiation, Cisplatin, Civil service commission, Pembrolizumab, Endometrial cancer, Nephrectomy, Platinum, MSI-H, Pemetrexed, Bevacizumab, Risk, Transitional cell carcinoma, CPS, PD-L1

Summary of opinion: Keytruda, 22/02/2024 Positive

Key Points: 


Summary of opinion: Keytruda, 22/02/2024 Positive

ChemoMouthpiece, LLC. Announces the Awarding of the 510(k) Marketing Clearance by the FDA for their Oncology Supportive Care Device and Recent Closing of their Private Placement Round

Retrieved on: 
星期四, 二月 22, 2024
Vasoconstriction, Incidence, Marketing, ONS, Oncology Nursing Society, Multimedia, ASCO, FDA, News, Pain, Hodgkin lymphoma, Cryotherapy, Nausea, Manuscript, Risk, Mouth, Society, Wastewater treatment, Patient, Chemotherapy, Clinical trial, Lymphoma, Mucositis, Dentistry

announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.

Key Points: 
  • announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.
  • has just closed on their Private Placement Round of $10 million in upfront capital with a full commitment for the second tranche of additional funds in excess of $10 million.
  • "Chemo Mouthpiece™ is fully stocked, as we will begin shipping across the US within the next quarter now that we have FDA Marketing Clearance.
  • ChemoMouthpiece, LLC is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients.

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Retrieved on: 
星期五, 一月 5, 2024
RNA, Medical Subject Headings, Brain, Marketing, Agency, Health, INN, Risk, Stomach, Ependymoma, ATC, Medulloblastoma, Radiation, International, Blood, Language, DNA, Literature, Hodgkin lymphoma, Chemotherapy, Cancer, Skin cancer, Glioblastoma, Astrocytoma, Haematopoiesis, European Medicines Agency, Neoplasm, Transplant, Select, Cell, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Physicians from American Oncology Network Selected to Present at the American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
星期四, 十二月 21, 2023
Physician, Research, Rituximab, Hodgkin lymphoma, Health, Doctor of Philosophy, Addition, Society, ASH, Abstract, AON, Clinical trial, Methylprednisolone, FACP

Each year, over 5,000 scientific abstracts undergo a meticulous and thorough peer review process, with only a select few earning acceptances for oral and poster presentations at the annual meeting and exposition.

Key Points: 
  • Each year, over 5,000 scientific abstracts undergo a meticulous and thorough peer review process, with only a select few earning acceptances for oral and poster presentations at the annual meeting and exposition.
  • The selected abstracts epitomize crucial and innovative research in the field.
  • “As physicians, we are on the front lines of patient care, and our research is an extension of that commitment.
  • “Their commitment to research and the betterment of patient care is a testament to the caliber of physicians we have at AON.

SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma

Retrieved on: 
星期三, 十一月 15, 2023
Food, T-cell lymphoma, FDA, Hodgkin lymphoma, MD, Diagnosis, CMO, Bone marrow, Pharmaceutical industry

HUMMELSTOWN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s lead product candidate, SIRPant-M™, an autologous SIRPαlow activated macrophage therapy, for the treatment of T-cell lymphoma.

Key Points: 
  • HUMMELSTOWN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s lead product candidate, SIRPant-M™, an autologous SIRPαlow activated macrophage therapy, for the treatment of T-cell lymphoma.
  • “Allowance of Orphan Drug Designation represents a significant milestone for the Company and is important recognition for the promise of our therapeutic platform,” said Robert Towarnicki, CEO of SIRPant.
  • “Unlike B-cell lymphomas and classical Hodgkin Lymphoma, many T-cell lymphoma subtypes do not have a suitable drug target, and approved cellular immuno-therapy is currently unavailable in T-cell lymphoma,” said Jelle Kijlstra, MD, CMO of SIRPant.
  • Sponsors of medicines that are granted Orphan Drug Designation are entitled to certain incentives and regulatory assistance, including tax credits for qualified clinical trials, prescription drug user-fee exemptions, and potential seven-year marketing exclusivity upon FDA approval.

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
星期二, 十一月 14, 2023
Webcast, Record, Safety, Annual general meeting, Cytokine release syndrome, Research, Type, Silicon Valley Bank, ASH, Non-Hodgkin lymphoma, CRS, International, Bank statement, Book, Silicon, Insurance, Patient, Genentech, FDA, Hodgkin lymphoma, Lung cancer, International Financial Reporting Standards, GVHD, Monroe Dunaway Anderson, International Accounting Standards Board, IASB, Cholangiocarcinoma, ORR, Roivant Sciences, Cancer, Trial of the century, Financial toxicity, Haematopoietic system, HL, EST, AML, Society, NHL, PTCL, NK, NSCLC, Cryptocurrency, Medical device, Vaccine, Pharmaceutical industry, Rare-earth element, Audit, Euro, Affimer

MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

Key Points: 
  • MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
  • Total revenue for the quarter ended September 30, 2023, was €2.0 million compared with €14.9 million for the quarter ended September 30, 2022.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on November 14, 2023, at 8:30 a.m. EST / 14:30 CET to discuss third quarter 2023 financial results and corporate developments.